Aug 21, 2025 • Benzinga
NEUTRAL
Why Is Ionis Pharma Stock Gaining Thursday? - Ionis Pharmaceuticals ( NASDAQ:IONS )
Dawnzera cut monthly HAE attacks by 81% vs placebo in Phase 3, with up to 87% reduction after second dose. Patients switching from Takhzyro or Orladeyo saw a 62% lower HAE attack rate with Dawnzera. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →
Aug 21, 2025 • Benzinga
SOMEWHAT-BULLISH
BioCryst to Present at Upcoming Investor Conference - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
Aug 21, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
Aug 12, 2025 • Zacks Commentary
NEUTRAL
Are Options Traders Betting on a Big Move in BCRX Stock?
Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.
Aug 11, 2025 • Benzinga
SOMEWHAT-BULLISH
BioCryst Announces Departure of Dr. Helen Thackray - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Aug 11, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
BioCryst Announces Departure of Dr. Helen Thackray
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the ...